Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05250817 · ClinicalTrials.gov registry record

A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by Bristol-Myers Squibb.

Completed
Registry status
501
Enrollment target
1
Study location

NCT05250817 is a study of Carcinoma, Non-Small Cell Lung that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 501 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (57% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05250817, a study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
501 participants
Enrollment target
1
Study location

Study Summary

The purpose of this observational study is to determine participants' preferences for outcomes associated with first-line treatment of advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) using a discrete-choice experiment (DCE).

Conditions Studied

Carcinoma, Non-Small Cell Lung

Study Locations (1)

North Carolina

  • RTI Health Solutions - Research Triangle Park

Trial Details

FieldValue
Enrollment Target 501 participants
Start Date 2021-12-09
Est. Completion 2023-01-04

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05250817

The ClinicalTrials.gov registry entry for NCT05250817 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (57% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 0 interventions.

NCT05250817 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05250817 about?

NCT05250817 is a clinical study titled "A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer". The purpose of this observational study is to determine participants' preferences for outcomes associated with first-line treatment of advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) using a discrete-choice experiment (DCE).

What is the current status of trial NCT05250817?

This trial is currently completed. The enrollment target is 501 participants. The study started on 2021-12-09. Estimated completion is 2023-01-04.

What conditions does trial NCT05250817 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

Who is sponsoring clinical trial NCT05250817?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05250817 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.